급성폐손상에 응고 및 섬유소 용해과정의 역할

키워드

참고문헌 (50)

1. Rubenfeld GD, "Incidence and outcomes of acute lung injury", N Engl J Med, 353, pp.1685~1693 (2005)
2. Bernard GR, "Efficacy and safety of recombinant human activated protein C for severe sepsis", N Engl J Med, 344, pp.699~709 (2001)
3. The Acute Respiratory Distress Syndrome Network, "Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome", N Engl J Med, 342, pp.1301~1308 (2000)
4. Bachofen M, "Structural alterations of lung parenchyma in the adult respiratory distress syndrome", Clin Chest Med, 3, pp.35~56 (1982)
5. Ware LB, "National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network: Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury", acute respiratory distress syndrome, 2007, pp.35, 1821~1828
6. Camerer E, "Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa", Proc Natl Acad Sci, 통권 : 97, pp.5255~5260 (2000)
7. Riewald M, "Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor", Proc Natl Acad Sci USA, 통권 : 98, pp.7743~7747 (2001)
8. Ruf W, "Specificity of coagulation factor signaling", J Thromb Haemost, 1, pp.1495~1503 (2003)
9. Ruf W, "Tissue factor-dependent coagulation protease signaling in acute lung injury", Crit Care Med, 31(3), pp.S231~S237 (2003)
10. Levi M, "Differential effects of anti-cytokine treatment on bronchoalveolar hemostasis in endotoxemic chimpanzees", Am J Respir Crit Care Med, 158, pp.92~98 (1998)
11. Dahlem P, "Alveolar fibrinolytic capacity suppressed by injurious mechanical ventilation", Intensive Care Med, 31, pp.724~732 (2005)
12. Sabharwal AK, "Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis", Am J Respir Crit Care Med, 151, pp.758~767 (1995)
13. Gando S, "Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients", Thromb Res, 109, pp.119~124 (2003)
14. de Moerloose P, "Procoagulant activity in bronchoalveolar fluids: no relationship with tissue factor pathway inhibitor activity", Thromb Res, 65, pp.507~518 (1992)
15. Creasey AA, "Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock", J Clin Invest, 91, pp.2850~2856 (1993)
16. Enkhbaatar P, "Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation", Am J Respir Crit Care Med, 162, pp.1752~1759 (2000)
17. Abraham E, "OPTIMIST Trial Study Group: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial", JAMA, 290, pp.238~247 (2003)
18. Warren BL, "KyberSept Trial Study Group: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial", JAMA, 286, pp.1869~1878 (2001)
19. Vincent JL, "A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome", Crit Care Med, 37, pp.2100~2101 (2009)
20. Esmon CT, "A new vitamin K-dependent protein. A phospholipid-binding zymogen of a serine esterase", J Biol Chem, 251, pp.3052~3056 (1976)
21. Esmon CT, "Role of coagulation inhibitors in inflammation", Thromb Haemost, 86, pp.51~56 (2001)
22. Shimuzu S, "Activated protein C inhibits the expression of platelet-derived growth factor in the lung", Am J Respir Crit Care Med, 167, pp.1416~1426 (2003)
23. Cheng T, "Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective", Nat Med, 9, pp.338~342 (2003)
24. Sakata Y, "Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor", Blood, 68, pp.1218~1223 (1986)
25. Hataji O, "Activation of protein C pathway in the airways", Lung, 180, pp.47~59 (2002)
26. Branson HE, "Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant", Lancet, 2, pp.1165~1168 (1983)
27. Seligsohn U, "Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn", N Engl J Med, 310, pp.559~562 (1984)
28. Taylor FB Jr, "Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon", J Clin Invest, 79, pp.918~925 (1987)
29. Yan SB, "Low levels of protein C are associated with poor outcome in severe sepsis", Chest, 120, pp.915~922 (2001)
30. Kalil AC, "Effects of drotrecogin alfa (activated) in human endotoxemia", Shock, 21, pp.222~229 (2004)
31. ) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia, "Blood", 2003, 2093~2098
32. Finigan JH, "The coagulation system and pulmonary endothelial function in acute lung injury", Microvasc Res, 77, pp.35~38 (2009)
33. Finigan JH, "Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation", J Biol Chem, 280, pp.17286~17293 (2005)
34. Isermann B, "Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis", Nat Med, 13, pp.1349~1358 (2007)
35. Fukudome K, "Identification, cloning, and regulation of a novel endothelial cell protein C", activated protein C receptor, 1994, pp.269, 26486~26491
36. Oganesyan V, "The crystal structure of the endothelial protein C receptor and a bound phospholipid", J Biol Chem, 277, pp.24851~24854 (2002)
37. Taylor FB Jr, "Endothelial cell protein C receptor plays an important role in protein C activation in vivo", Blood, 97, pp.1685~1688 (2001)
38. Abraham E, "Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death", N Engl J Med, 353, pp.1332~1341 (2005)
39. Liu KD, "Randomized clinical trial of activated protein C for the treatment of acute lung injury", Am J Respir Crit Care Med, 178, pp.618~623 (2008)
40. Mondino A, "uPA and uPAR in fibrinolysis, immunity and pathology", Trends Immunol, 25, pp.450~455 (2004)
41. Yepes M, "New functions for an old enzyme: nonhemostatic roles for tissue-type plasminogen activator in the central nervous system", Exp Biol Med (Maywood), 229, pp.1097~1104 (2004)
42. Ware LB, "Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury", Am J Physiol Lung Cell Mol Physiol, 291, pp.L307~L311 (2006)
43. Kwak SH, "Plasminogen activator inhibitor-1 potentiates LPS-induced neutrophil activation through a JNK-mediated pathway", Thromb Haemost, 95, pp.829~835 (2006)
44. Abraham E, "Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation", J Immunol, 170, pp.5644~5651 (2003)
45. Park YJ, "PAI-1 inhibits neutrophil efferocytosis", Proc Natl Acad Sci USA, 통권 : 105, pp.11784~11789 (2008)
46. Kwak SH, "The kringle domain of urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation through interaction with {alpha}V{beta}3 integrins", J Leukoc Biol, 78, pp.937~945 (2005)
47. Wang XQ, "Involvement of the urokinase kringle domain in lipopolysaccharide- induced acute lung injury", J Immunol, 177, pp.5550~5557 (2006)
48. Arndt PG, "Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator Inhibitor-1 through a JNK-mediated pathway", J Immunol, 175, pp.4049~4059 (2005)
49. Tsuruta Y, "Involvement of vitronectin in lipopolysaccaride-induced acute lung injury", J Immunol, 179, pp.7079~7086 (2007)
50. Singh B, "Expression of angiostatin, integrin alphavbeta3, and vitronectin in human lungs in sepsis", Exp Lung Res, 31, pp.771~782 (2005)

관련 논문AI추천